Terms and Conditions

By using this site you acknowledge that Genentech, Inc. and Biogen Idec Inc. are providing the material for informational purposes only and that neither Genentech, Inc. nor Biogen Idec Inc. nor their agents, affiliates, partners, or licensors are providing the materials to you for the purposes of giving you medical advice. You should not rely on the materials in deciding on a treatment plan, drug usage, or any other medical advice regarding the materials, and Genentech, Inc., Biogen Idec Inc., and their licensors strongly urge that you consult with a physician in connection with any and all treatment options that may be available to you.

By using this website, you accept the information, products, and services provided herein "as is". Genentech, Inc. and Biogen Idec Inc. make no express or implied warranty regarding the accuracy, content, completeness, reliability, operability, or legality of information contained within this website, including, without limitation, the warranties of merchantability, fitness for a particular purpose, and non-infringement of proprietary rights.

In no event shall Genentech, Inc., Biogen Idec Inc., or its agents, affiliates, partners, or licensors be liable for any direct, special, indirect, incidental or consequential damages or any damages whatsoever resulting from loss related to the use of our websites, whether in an action of contract, breach of warranty, negligence, or other tortious action arising out of or in connection with the use of the materials contained on this site.


Indications

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent

People with serious infections should not receive RITUXAN.

Important Safety Information

  • RITUXAN can cause serious side effects that can lead to death, including infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
  • RITUXAN has also been associated with serious and life-threatening side effects, including the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
  • The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
  • Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including Medication Guide.

CVP=cyclophosphamide, vincristine, and prednisone or prednisolone; CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone.